On July 19, I read a press release that annouced that:
Rabin Martin, a leading global management consultancy working at the crossroads of health, announced today that Dr. Jeffrey L. Sturchio, President & Chief Executive Officer of the Global Health Council, will join the firm in September as Senior Partner. Sturchio will guide strategy, identify emerging issues and create new partnerships for the firm’s corporate, multilateral and nonprofit clients.
I wrote Jeffrey Sturchio a note asking about the move, and he wrote back to tell me that “Yes, I am leaving the Global Health Council on August 15.”
According to the press release, Sturchio’s appointment followed other recent management additions at Rabin Martin, including: David Golub (formerly eight years of service with the American Cancer Society), Julie Becker (worked with International AIDS Vaccine Initiative, HealthRight International, EngenderHealth and the International Planned Parenthood Federation), and Maria Schneider (worked at Edelman and the Pfizer Foundation and as an independent consultant, with clients including the Business Roundtable, Lance Armstrong Foundation, UNICEF and Harvard School of Public Health).
I had never heard of Rabin Martin before, and in preparing for the UN negotiation on NCDs, I wanted to take a look at the firm. The two principles are Steve Rabin, formerly with Ogilvy Public Affairs and Porter Novelli, and Bill Martin, who, among other things, previously ” directed internal change communications for Merck’s corporate turnaround effort and led the company’s Vioxx withdrawal communications, and “was the senior communications and investor relations officer at two biotech companies.
These are a few highlights from the company web page:
Expertise: IP and Patent Protection
Our work in developing intellectual property strategies helps protect clients’ long-term investments in research while at the same time meeting urgent health needs. We’ve helped our clients with this delicate balance by:
- Monitoring the impact of Indian patent law on access and industry
- Responding to unlicensed manufacturing and sales
- Designing approaches for the licensing of intellectual property
- Announcing drug licensing agreements
- Assessing strategies for patent pooling
- Reviewing the intellectual property policies of leading innovator companies
Expertise Global Health
We’ve worked with clients in addressing concerns like these through:
- Convening consensus conferences at the United Nations
- Designing approaches for the licensing of intellectual property
- Analyzing drug pricing strategies for middle income countries
- Monitoring stakeholders and emerging health events on six continents
- Introducing global health experts to the business community in emerging markets
- Developing and guiding advisory boards of international health experts
Healthcare Reform & Innovation
We’ve worked with clients to engage in this ongoing debate through:
- Legislative and regulatory analysis
- Development of principles for legislation
- Primers and white papers on primary care for policymakers
- Establishing and managing advocacy coalitions
- Capitol Hill briefings
- Forums for media and stakeholders
- Grassroots action kits
- Op-eds for key districts
- New approaches to patient education and privacy legislation
- Use of text messaging by public health agencies
- Legislation and regulatory tracking on marketing and advertising restrictions
Some other items from the web page include:
- Addressing concerns about over-prescribing of medicines and off-label medicine use
- Bringing women’s health experts together with business leaders in emerging markets
- Brokering interaction between business representatives and healthcare leaders in emerging markets
- Capitol Hill briefings
- Conducting a summit on mental health issues in the American Indian community
- Convening a consensus conference on women and clinical trial design at the United Nations
- Convening a mainstream media symposium on mental health issues
- Convening a Washington forum with major opinion leaders and journalists to discuss treatment issues
- Coordinating communications that support global safety-related product announcements, regulatory communications and worldwide product withdrawals
- Creating programs to protect and enhance a pharmacist’s obligation to provide counsel in-pharmacy to patients
- Creating school-based screening programs
- Creating transparency guidelines for adverse event collection and reporting
- Designing and conducting crisis management simulations in Mexico and Thailand
- Designing new approaches to teen mental health screenings
- Designing risk management programs to encourage appropriate use
- Developing forecasts on medicine use in sub Saharan Africa
- Developing initiatives to expand private insurance reimbursement for mental health services
- Developing positions on women’s health research for a global healthcare company
- Developing primers and white papers on adolescent healthcare for policymakers
- Development of principles for legislation
- Drafting principles for state and federal children’s health legislation
- Engaging the Honduran government and Merck to expand access to childhood vaccines
- Establishing and directing a patient group coalition in California
- Establishing and managing advocacy coalitions
- Establishing and managing coalitions of mental health and suicide prevention groups
- Establishing approaches to pediatric medicines for a global healthcare company
- Establishing corporate guidelines for monitoring and reporting safety information in digital channels
- Forums for media and stakeholders
- Grassroots action kits
- Legislation and regulatory tracking on marketing and advertising restrictions
- Legislative and regulatory analysis
- Managing negotiations between the Robert Wood Johnson Foundation and New York Times Digital
- New approaches to patient education and privacy legislation
- Op-eds for key districts
- Preparing infectious disease industry/competitor analysis
- Primers and white papers on primary care for policymakers
- Publicizing developing world infectious disease research initiatives
- Supporting industry and NGO collaboration on microbiocide research and development.
- Supporting large collaborative surveillance programs
- Use of text messaging by public health agencies
- Working in Washington and state capitols to advance mental health legislative and regulatory initiatives
These are the clients listed on the web page.
Corporations
Pharmaceutical:
- Forest Laboratories
- Janssen Pharmaceutica
- Johnson & Johnson
- Merck
- Ortho-McNeil
- Pfizer
- PriCara
- Solvay Pharmaceuticals (owned by Abbott)
- Tibotec
- Tibotec Therapeutics
Health Information Technology:
- Catalina Health Resource
- General Electric Medical Systems
Non-Profits, Philanthropies and the Public Sector
Non-Profits/ Non-Governmental Organizations:
- Columbia University
- Foundation Center
- Global Campaign for Microbicides
- International Treatment Preparedness Coalition
- Make A Wish Foundation
- Tibotec Global Access Program
- Union Theological Seminary
- Women’s eNews
Foundations:
- The NoVo Foundation
- The Robert Wood Johnson Foundation
- The TY Danjuma Foundation
- United Nations Foundation
Public Health Entities & Initiatives:
- Black Treatment Advocates Network
- The National Center for Mental Health Checkups at Columbia University
- The U.S. Centers for Disease Control and Prevention
Comments are closed.